Clinical Trial Search

Primary: Change in Spontaneous Pain at 60-120 Minutes After Lidocaine Infusion Initiated (Assessed on 0-10 NRS) — 33; 51 percentage of pain change from baseline — p=0.03

Primary: Change From Baseline in Weekly Mean 24-hour Average Pain Severity (APS) Score at 5 Weeks — -2.08; -2.22; -2.45; -2.42 units on a scale

Primary: Numeric Rating Scale (NRS) Pain Intensity — -0.83; -0.45 units on a scale — p=0.47

Primary: Change From Baseline to End of Treatment (EOT) in Weekly Mean Pain Score on the Daily Pain Rating Scale (DPRS) — -3.8 scores on scale — p=< 0.0001

Primary: Mean Change From Baseline to Week 5 in Average Daily Pain Score (ADPS) Following Treatment With DS-5565 Compared to Pregabalin and Placebo — -1.86; -1.79; -2.04; -2.32…

Primary: Change From Week 8 to Week 16 Endpoint in 24 Hour Average Pain Item Score on the Brief Pain Inventory (BPI) Modified Short Form — -2.353; -2.161 units on a scale — p=0.370

Primary: Change in Patient Quality of Life at Baseline and 8 Months — 0.66; 0.65; 0.68; 0.68 units on a scale

Primary: Change From Single-Blind Baseline in Mean Pain Score at Week 19 During Double-Blind Phase — 6.8; 6.7; -3.9; -3.5 units on a scale — p=0.1221

Primary: Change From Baseline to Study Endpoint in Mean Weekly Pain Scores — -1.20; -1.82; -1.94 score on scale — p=0.0075

Primary: Measurement of b-FGF, v-EGF MEASURED BY ELISA — 30.2; 55.4; 30.3; 428.7 pg/ml — p=0.005

Primary: Change in Average Daily Pain Score From Baseline Week to the Last 4 Weeks of the Maintenance Phase — -1.9; -2.2; -2.4 units on a scale — p==0.0410

Primary: Treatment-emergent Adverse Events for Participants Who Received Engensis 4 mg, 8 mg, or 16 mg — 3; 2; 2; 1 Participants

Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84

Primary: Change From Baseline at Week 12 in Average Pain Severity Rating Using Diaries for the Combined Duloxetine Arms (40 mg + 60 mg) — -1.61; -2.47 units on a scale — p=<0.0001

Primary: Change From Baseline to Week 4 in the Weekly Average of the Daily Pain Score as Derived From the Subject's Responses on the Pain Intensity Numerical Rating Scale…

Primary: Baseline Mean Pain Score — 6.65; 6.67 units on a scale

Primary: Change From Baseline to 12 Week Endpoint in Brief Pain Inventory 24-hour Average Pain Score — -2.69; -2.31 units on a scale — p=0.617

Primary: Gracely Pain Scale (GPS) — -2.51; -1.96; -2.38; -0.99 GPS pain score on a scale

Primary: Changes in Small Nerve Fiber Density by Assessment of a Skin Biopsy Comparing Baseline to Day 60 — .1; .1 nerve fibers / mm squared

Primary: Numeric Rating Scale (NRS) Average Pain Intensity — -1.50; -1.61; -1.15; -1.23 score on a scale

Primary: Assessing the Change in Resting Blood Pressure Upon Treatment of Pregabalin vs. Placebo in Patients With Diabetes and Peripheral Neuropathy. — -7.63; -8.98; -4.41; -4.93…

Primary: Number of Participants Who Experienced an Adverse Event (AE) — 11; 22; 126; 121 participants

Primary: Pain Assessment — 6.5; 1.0 score on a scale

Primary: Change From Baseline to Week 12 in the Average Daily Pain NPRS (Numeric Pain Rating Scale) Score; mLOCF Imputation — -1.9; -2.4; -1.5; -2.7 units on a scale — p=0.168

Primary: Skin Biopsy - Intraepidermal Nerve Fiber Density (IENFD) - Distal Thigh — 12; 14 Percentage change in IENFD

Primary: Change in Average Pain Scores From Baseline to Week 15/End of Treatment (EOT) — -2.22; -1.73; -1.30; -1.85 Scores on a Scale

Primary: Mean Neuropathic Pain Score at Visit 3 (Week 1) — 51.00; 50.70 Units on a Scale

Primary: Change in Clinic Visit Pain Score at the 12 Week Visit Compared to Baseline as Assessed by the 11-point Likert Numerical Rating Scale (NRS) — 6.2; 6.6; 6.6; 6.5 Scores…

Primary: Average Diabetic Peripheral Neuropathy (DPN) Pain Based on a Numeric Rating Scale (NRS) Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)…

Primary: Change From Baseline in Mean Numeric Pain Rating Scale (NPRS) Score — 1.02; 1.74; 1.51 units on a scale